Abstract
A new clinical trial suggests that the MEK inhibitor selumetinib induces partial responses in children with neurofibromatosis type 1 who have inoperable plexiform neurofibromas. The drug led to confirmed partial responses in 70% of patients; progression-free survival was 84% after 3 years.
©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.